Climb Bio starts IgA nephropathy trial of CLYM116 with $227.6m in the bank

Climb Bio reported $227.6m in cash on 5 November with its third-quarter results, and says that is enough to run the company until the latter part of 2028. The release summary gave no other financial detail, such as burn rate or operating loss, and the full text of the release was not available to CompePharma.

The commercial question for CLYM116, an anti-APRIL antibody, is how often patients would need to take it. Phase 1 work in healthy volunteers showed that levels of free APRIL stayed suppressed out to 12 weeks. The company says this supports a dosing schedule of once every 12 weeks. Dosing has now started in NAVIGATE-2, a Phase 2 trial in IgA nephropathy, where the interval will have to be shown in patients rather than healthy volunteers.

The company's second asset, budoprutug, targets CD19. Climb Bio describes B-cell depletion and a favourable safety profile in studies in primary membranous nephropathy and lupus. It will present further data in immune thrombocytopenia (ITP) at the American Society of Hematology meeting in December.

Because budoprutug is being tested across several autoimmune conditions, safety findings from each patient group are likely to shape later conversations with regulators. The summary did not detail the trial designs, sample sizes or efficacy figures.